CTHIn ForceLegislation
National Health (Botulinum Toxin Program) Special Arrangement 2025
9Supply of botulinum toxin pharmaceutical benefits under this instrument
Start here
Get a plain-English read of 9
Turn the raw legal text into a practical explanation grounded in National Health (Botulinum Toxin Program) Special Arrangement 2025.
#### 9 Supply of botulinum toxin pharmaceutical benefits under this instrument
(1) A supply of a botulinum toxin pharmaceutical benefit to a person is a special arrangement supply of the benefit if:
(a) the person is an eligible patient for the benefit; and
(b) the benefit is supplied by an approved hospital authority; and
(c) the benefit is directly administered to the person by an eligible medical practitioner for the person and the benefit; and
(d) a valid prescription for supply of the benefit to the person is given or presented to the approved hospital authority:
(i) prior to the supply; or
(ii) within 7 days after the eligible medical practitioner administered the benefit; and
(e) if, under paragraph 85A(2)(a) of the Act, the Minister has determined that a maximum quantity or number of units of the benefit, or pharmaceutical item in the benefit, applies in relation to the supply of the benefit on any one occasion either for all purposes, or for the purpose for which the supply was made—the prescription directs the supply of less than or equal to that maximum quantity or number; and
(f) if, under subsection 85A(2A) of the Act, the Minister has determined that particular conditions must be satisfied when writing a prescription to which a determination referred to in paragraph (e) of this subsection applies—the conditions are satisfied.
> Note: Under this instrument, the supplier of a botulinum toxin pharmaceutical benefit cannot physically supply or hand the benefit directly to an eligible patient.
(2) The following sections of the National Health (Pharmaceutical Benefits) Regulations 2017 do not apply in relation to a special arrangement supply of a botulinum toxin pharmaceutical benefit:
(a) section 48 (about supply of pharmaceutical benefits before surrender of written prescription);
(b) section 49 (about circumstances in which quantity of repeated supply can be directed to be supplied on one occasion);
(c) section 55 (about presentation of urgent prescriptions).